Rosuvastatin lowers LDL slightly more than atorvastatin; LODESTAR outcomes were similar
Comparison of the two high-intensity statins: both lower LDL-C by 50% or more, rosuvastatin is more potent per milligram, but in the randomized LODESTAR trial 3-year clinical outcomes did not differ significantly. The goal is reaching the appropriate LDL target on maximally tolerated therapy.


